Innovent Biologics (HK:1801) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Innovent Biologics has announced that China’s National Medical Products Administration (NMPA) accepted the New Drug Application for picankibart, a treatment for moderate to severe plaque psoriasis. The drug, an IL-23p19 antibody, demonstrated high efficacy and safety in Phase 3 trials, with promising results such as over 80% of subjects achieving significant skin lesion clearance. Picankibart is poised to improve treatment convenience and quality of life for patients, backed by Innovent’s commitment to meet regulatory standards for a better treatment option in China.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.